Tardive Dyskinesia News

Research and Markets: Dyskinesia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Research and Markets has announced the addition of GlobalData's new report "Dyskinesia Therapeutics - Pipelin
Synchroneuron Completes $6 Million Series A Financing to Fund Development of a Novel Treatment for Movement Disorders
Synchroneuron Inc., a privately-held biopharmaceutical company, today announced the completion of its Series A financing with a $6 million investment from Morningside Technology Ve
Neurocrine Biosciences Announces The FDA Has Granted Fast Track Designation For VMAT2 Inhibitor NBI-98854
SAN DIEGO, Jan. 25, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX - News) announced today that its VMAT2 inhibitor product candidate, NBI-98854, has been granted Fast Track designation by the ...
Synchroneuron Raises $6M Series A
Synchroneuron Inc., a privately-held biopharmaceutical company, today announced the completion of it...
Synchroneuron Completes $6 Million Series A Financing
WALTHAM, Mass.--(BUSINESS WIRE)--Synchroneuron Inc., a privately-held biopharmaceutical company, tod...
Medicure Provides Update on TEND-TD Phase II Clinical Trial
WINNIPEG, MANITOBA-- - Medicure Inc. is pleased to provide an update and announce the addition of a site in India for its ongoing Phase II Clinical Trial, TardoxalTM for the Treatment of Tardive Dyskinesia . The company has received approval from the Drug Controller General of India and anticipates enrollment ...
Press Release
Synchroneuron Inc. Posted on:07 Feb 12 Synchroneuron Inc., a privately-held biopharmaceutical company, today announced the completion of its Series A financing with a $6 million investment from Morningside Technology Ventures Ltd.
Neurocrine Biosciences Reports Fourth Quarter and Year End 2011 Results
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX - News) today announced its financial results for the quarter and year ended December 31, 2011.For the fourth quarter of 2011, ...
Synchroneuron focuses new funds on movement disorder drug
Synchroneuron Inc., a biotech company that emerged from stealth mode Monday with a $6 million Series A financing, said it will use the funds to finish developing a new formulation for a chemical compound that is approved for other indications, company executives told Mass High Tech in an interview.
Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX - News) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting ...